Lupus NephritisPhase 3NCT07767188
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
A Phase 3 study testing obinutuzumab (RO5072759) in people with Lupus Nephritis, run by Zhao Minghui at 14 sites in China.
Trial summary
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Lupus Nephritis
- What is being tested?
- obinutuzumab (RO5072759)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 14 sitesChina
- Study dates
- 10 Sep 2026to 8 May 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed Informed Consent Form
- Age 18 to 65 years at time of signing Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- ISN/RPS 2003 Class III, IV, V active/active chronic LN by renal biopsy performed within the 1 month prior to screening or during screening with 24hUPCR≥1g/g
- SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria, which are met by the presence of Class III- V LN or mixed Class LN, and current or past positive antinuclear antibody (ANA) Positive ANA is defined by ANA at a titer of ≥ 1:80 on HEp-2 cells or an equivalent positive ANA test at least once.
- Receipt of at least one dose of pulse methylprednisolone IV (≥250 mg) or equivalent for treatment of the current episode of active LN during the 1 month prior to screening or during screening
- A maximum of 3 g methylprednisolone IV or equivalent d during the 4 weeks prior to screening or during screening is allowed.
Who cannot join
- Are pregnant or breastfeeding.
- Have severe renal impairment, defined as eGFR < 30 mL/min/1.73 m² (estimated using the CKD-EPI equation), or require dialysis or renal transplantation.
- Have renal biopsy showing > 50% glomerular sclerosis.
- Have pure chronic renal biopsy findings: no active lesions.
- Have rapidly progressive glomerulonephritis.
- Have active gastrointestinal ulcer.
- Have intolerance or contraindication to the study treatment.
Trial locations and contacts
14 sites in 1 country. Contact the study team or a site near you to ask about taking part.
14 sites in 1 country
China14 sites
Peking University First Hospital
Beijing
Fujian Medical University Union Hospital
Fuzhou, Fujian
Chief Physician, +86 18050288838, lixinwei66@126.com
Guangdong Provincial People's Hospital
Guangzhou, Guangdong
Chief Physician, 15820264379@139.com
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong
Chief Physician, +86 13189097222, longhb1966@163.com
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang
Chief Physician, +86 15776613376, suimanshu@163.com
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan
Chief Physician, +86 13679676835
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi
Chief Physician, +86 138 7919 0111
Jiangsu Province Hospital
Nanjing, Jiangsu
Chief Physician, +86 13851746819, huijuanmao2026@163.com
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning
Chief Physician, huazhou_clintrial@163.com
Tianjin Medical University General Hospita
Tianjin, Tianjin Municipality
Chief Physician, nkxpc@163.com
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang
Chief Physician, +86 13579416340, lisuhuanh@sina.com
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi
Chief Physician, 15291185506, pipifu@126.com
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu
Chief Physician, +86 15862158578, sundongxz@126.com
Yantai Yuhuangding Hospital
Yantai, Shandong
Chief Physician, 18663819062, wudaoxu@qdu.edu.cn
About this study
Official title: A Prospective, Multicenter Trial to Explore the Efficacy and Safety of Obinutuzumab Adds on to Standard-of-care Therapy Consisting of Mycophenolate Mofetil (MMF) and Corticosteroids (O-triple) as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients
- Conditions
- Lupus Nephritis
- Being tested
- obinutuzumab (RO5072759)
- Medical subject headings
- Lupus Nephritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
obinutuzumab (RO5072759)Drug
Patients will receive Obinutuzumab 1000 mg at day1 (week 0) and weeks 2, 24, 26, and 52, in combination with glucocorticoids and MMF.
| Study group | Role | What they receive |
|---|---|---|
| O-triple therapy | Experimental | Obinutuzumab add on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids (O-triple) in initial active LN patients. Receives: Drug: obinutuzumab (RO5072759) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients who achieve a complete renal response (CRR) at Week 76
Urinary protein-to-creatinine ratio (UPCR) <0.5 g/g eGFR ≥ 85% of baseline, as calculated using the CKD-EPI equation No occurrence of intercurrent events (rescue therapy, treatment failure, and early study withdrawal are considered as intercurrent events).
Measured: Baseline, Week 76
Secondary outcomes (1)
The proportion of patients who achieve ORR (CRR or PRR), CRR, PRR, PERR at week 24, week 36, week 52, week 76
Measured: Baseline week 24, week 36, week 52, week 76
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2026
- Study start10 Sep 2026 (estimated)
- Primary completion27 Feb 2029 (estimated)
- Study completion8 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lupus NephritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhao Minghui
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Zhao Minghui, Peking University First Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07767188
- Sponsor's protocol ID
- 2026R0300
- Status last verified
- Aug 2026
- First submitted
- 11 Aug 2026
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicenter Trial to Explore the Efficacy and Safety of Obinutuzumab Adds on to Standard-of-care Therapy Consisting of Mycophenolate Mofetil (MMF) and Corticosteroids (O-triple) as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
- ClinicalTrials.gov ID
- NCT07767188
- Acronym / sponsor ID
- 2026R0300
- Conditions
- Lupus Nephritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Zhao MinghuiUniversity, hospital or other
- Study start
- 10 Sep 2026 (estimated)
- Primary completion
- 27 Feb 2029 (estimated)
- Study completion
- 8 May 2029 (estimated)
- First posted
- 17 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| O-triple therapy | Experimental | Drug: obinutuzumab (RO5072759)Obinutuzumab add on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids (O-triple) in initial active LN patients. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Signed Informed Consent Form
- Age 18 to 65 years at time of signing Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- ISN/RPS 2003 Class III, IV, V active/active chronic LN by renal biopsy performed within the 1 month prior to screening or during screening with 24hUPCR≥1g/g
- SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria, which are met by the presence of Class III- V LN or mixed Class LN, and current or past positive antinuclear antibody (ANA) Positive ANA is defined by ANA at a titer of ≥ 1:80 on HEp-2 cells or an equivalent positive ANA test at least once.
Key exclusion criteria (7 listed)
- Are pregnant or breastfeeding.
- Have severe renal impairment, defined as eGFR < 30 mL/min/1.73 m² (estimated using the CKD-EPI equation), or require dialysis or renal transplantation.
- Have renal biopsy showing > 50% glomerular sclerosis.
- Have pure chronic renal biopsy findings: no active lesions.
- Have rapidly progressive glomerulonephritis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| obinutuzumab (RO5072759)Patients will receive Obinutuzumab 1000 mg at day1 (week 0) and weeks 2, 24, 26, and 52, in combination with glucocorticoids and MMF. | Drug | O-triple therapy |
Primary outcome
Proportion of patients who achieve a complete renal response (CRR) at Week 76
Time frame: Baseline, Week 76
Urinary protein-to-creatinine ratio (UPCR) <0.5 g/g eGFR ≥ 85% of baseline, as calculated using the CKD-EPI equation No occurrence of intercurrent events (rescue therapy, treatment failure, and early study withdrawal are considered as intercurrent events).
1 secondary outcome
The proportion of patients who achieve ORR (CRR or PRR), CRR, PRR, PERR at week 24, week 36, week 52, week 76
Time frame: Baseline week 24, week 36, week 52, week 76
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: Yes
Related trials for Lupus Nephritis
RecruitingPhase 4
Dapagliflozin in Active Lupus Nephritis
Lupus Nephritis (LN)
RecruitingPhase 1
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Lupus Erythematosus, Systemic
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
RecruitingPhase 1/2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Autoimmune Disorders, Systemic Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing obinutuzumab (RO5072759) in people with Lupus Nephritis, run by Zhao Minghui at 14 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Minghui Zhao (+86 135 0124 3815, mhzhao@bjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients who achieve a complete renal response (CRR) at Week 76 (time frame: Baseline, Week 76). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.